AstraZeneca得到印度批准 向高级肺癌患者出售Osimertinib AstraZeneca gets Indian approval to sell Osimertinib for advanced lung cancer patients.

CDSCO已经批准印度AstraZeneca公司进口、销售和分发Osimertinib片,这是一种治疗非小细胞肺癌的药物。 AstraZeneca India has been approved by the CDSCO to import, sell, and distribute Osimertinib tablets, a drug for treating non-small cell lung cancer. 此项批准为患晚期、无法解剖的肺癌的病人提供了一种新的治疗选择,在化疗后出现EGFR突变。 This approval offers a new treatment option for patients with advanced, unresectable lung cancer with EGFR mutations after chemoradiation. AstraZeneca的国家总统Sanjeev Panchal强调了这一里程碑对于改善印度肺癌治疗的重要性。 AstraZeneca's Country President, Sanjeev Panchal, highlighted the importance of this milestone in improving lung cancer treatment in India.